SCHEMBL769792

SCHEMBL769792

COC(=O)C(C)(CO[Si](C)(C)C(C)(C)C)CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.34
BACE1 P56817 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769048 0.86 DGAT1 (0.37) DGAT1BACE1
SCHEMBL2218878 0.84 DGAT1 (0.32) DGAT1
SCHEMBL6835334 0.81 TSHR (0.39)
SCHEMBL2886068 0.76
SCHEMBL2886070 0.76
SCHEMBL22164540 0.76 DGAT1 (0.38) DGAT1
SCHEMBL22164539 0.76 DGAT1 (0.38) DGAT1
SCHEMBL5529022 0.72 TSHR (0.39) BACE1
SCHEMBL2203061 0.72 MAPT (0.31)
SCHEMBL161037 0.72 CYP2C9 (0.35) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754207-B2 Process for the preparation of rapamycin derivatives CADILA HEALTHCARE LIMITED (IN) 2014-06-17 US claimed
US-20120202988-A1 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES CADILA HEALTHCARE LIMITED (IN) 2012-08-09 US claimed
EP-2480557-A2 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES Cadila Healthcare Limited (IN) 2012-08-01 EP claimed
WO-2011051960-A2 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES CADILA HEALTHCARE LIMITED (IN) 2011-05-05 WO claimed
US-8754207-B2 Process for the preparation of rapamycin derivatives CADILA HEALTHCARE LIMITED (IN) 2014-06-17 US disclosed
US-8551963-B2 Imidazolothiazole compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2013-10-08 US disclosed
US-8551963-B2 Imidazolothiazole compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2013-10-08 US disclosed
US-20120202988-A1 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES CADILA HEALTHCARE LIMITED (IN) 2012-08-09 US disclosed
EP-2480557-A2 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES Cadila Healthcare Limited (IN) 2012-08-01 EP disclosed
US-20120070410-A1 IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION 2012-03-22 US disclosed
US-20120070410-A1 IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION 2012-03-22 US disclosed
EP-2358725-A1 Imidazolothiazole compounds as modulators of protein kinase Ambit Biosciences Corporation (US) 2011-08-24 EP disclosed
WO-2011051960-A2 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES CADILA HEALTHCARE LIMITED (IN) 2011-05-05 WO disclosed
WO-2010054058-A1 IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE AMBIT BIOSCIENCE CORPORATION (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202988-A1 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES RICTOR, MTOR, RPTOR DGAT1 4145/4885BACE1 1923/4885
US-20120070410-A1 IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF GRK2, GRK3, GRK4 DGAT1 2600/4885BACE1 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.